-
All Resources
(choose a category)
-
All Resources
-
selected
Evidence
Evidence, advice, guidance and standards
-
Improvement
Improvement and implementation support
-
selected
Scrutiny
Assurance, scrutiny, measurement and reporting
-
-
Healthcare Area
- Blood and immune system
- Cancer
- Cardiovascular system
- Dermatology
- Digestive system
- Ear, nose and throat
- Endocrine, nutritional and metabolic
- Eye
- Genitourinary system
- Infectious disease
- Injuries, accidents and wounds
- Mental and behavioural disorders
- Mouth and dental
- Musculoskeletal system
- Nervous system
- Obstetrics and gynaecology
- Respiratory system
-
Resource Type
- NICE Guidance
- Programme
- Year
- prev
- Page 4 of 3
27 results found filtered by Evidence Remove Evidence Filter Scrutiny Remove Scrutiny Filter 2011 Remove 2011 Filter 2010 Remove 2010 Filter 2009 Remove 2009 Filter NICE Guidance Remove NICE Guidance Filter Clear Search
-
STA Guidance No 239 – Fulvestrant for the treatment of locally advanced or metastatic breast cancer
- Published
- 14 December 2011
- Cycle of Improvement
- Evidence
-
STA Guidance No 238 – Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
- Published
- 14 December 2011
- Cycle of Improvement
- Evidence
-
STA Guidance No 240 – Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer
- Published
- 14 December 2011
- Cycle of Improvement
- Evidence
-
NICE STA Guidance No 237 – Ranibizumab for the treatment of diabetic macular oedema
- Published
- 30 November 2011
- Cycle of Improvement
- Evidence
-
STA 235 - Mifamurtide for the treatment of osteosarcoma
- Published
- 26 October 2011
- Cycle of Improvement
- Evidence
-
STA 236 – Ticagrelor for the treatment of acute coronary syndromes
- Published
- 26 October 2011
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 84 - The use of drotrecogin alfa (activated) for severe sepsis
- Published
- 25 October 2011
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 234 – abatacept for the treatment of rheumatoid arthritis
- Published
- 24 August 2011
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 233 – golimumab for the treatment of ankylosing spondylitis
- Published
- 24 August 2011
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 229 – Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal
- Published
- 27 July 2011
- Cycle of Improvement
- Evidence